Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000689318> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2000689318 endingPage "765" @default.
- W2000689318 startingPage "754" @default.
- W2000689318 abstract "Despite the conventional and high-dose chemotherapy with hematopoietic stem cell transplantation, multiple myeloma eventually relapses, resulting in an incurable hematological malignancy. Therefore, novel therapeutic approaches in clinical settings are desired. Recently, thalidomide was introduced for the treatment of myeloma, and many clinical trials have since confirmed its efficacy in patients with relapsed/refractory or newly diagnosed multiple myeloma. Multiple mechanisms have been proposed to explain thalidomides antimyeloma activity. However, the precise mechanism underlying this activity remains unclear, because thalidomide rapidly undergoes spontaneous, nonenzymatic, hydrolytic cleavage to numerous metabolites in vivo. To elucidate the exact anti-myeloma mechanism of thalidomide in vivo, we have performed structural development studies of thalidomide, and obtained various analogs with specific molecular properties. Among these derivatives, we found that a new thalidomide analog, 2-(2,6-diisopropylphenyl)-5-hydroxy-1H-isoindole- 1,3-dione (5HPP-33), has the most potent anti-myeloma effect with tubulin polymerization inhibiting activity. 5HPP-33 directly inhibited the growth and survival of various myeloma cells in a dose-dependent manner with IC50 of 1-10 μM. In contrast, thalidomide itself did not inhibit RPMI8226 cell growth. A tubulin polymerization assay using microtubule protein from porcine brain revealed that 5HPP-33 had potent tubulin polymerization inhibiting activity with IC50 of 8.1 μM, comparable to that of rhizoxin, a known tubulin polymerization inhibitor. Moreover, its activity was more potent than that of a known thalidomide metabolite, 5-hydroxythalidomide. Our data suggest that 5HPP-33 is a promising candidate as a therapeutic agent for multiple myeloma. In addition, the results suggest that thalidomides tubulin polymerization inhibiting activity might be the mechanism underlying the induction of apoptosis in myeloma cells. Keywords: Thalidomide, multiple myeloma, structural development, metabolite, 5HPP-33, tubulin polymerization inhibitor, apoptosis" @default.
- W2000689318 created "2016-06-24" @default.
- W2000689318 creator A5012278399 @default.
- W2000689318 creator A5013090266 @default.
- W2000689318 date "2008-04-01" @default.
- W2000689318 modified "2023-10-14" @default.
- W2000689318 title "New Tubulin Polymerization Inhibitor Derived from Thalidomide: Implications for Anti-Myeloma Therapy" @default.
- W2000689318 doi "https://doi.org/10.2174/092986708783955473" @default.
- W2000689318 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18393844" @default.
- W2000689318 hasPublicationYear "2008" @default.
- W2000689318 type Work @default.
- W2000689318 sameAs 2000689318 @default.
- W2000689318 citedByCount "11" @default.
- W2000689318 countsByYear W20006893182012 @default.
- W2000689318 countsByYear W20006893182015 @default.
- W2000689318 countsByYear W20006893182017 @default.
- W2000689318 countsByYear W20006893182020 @default.
- W2000689318 countsByYear W20006893182022 @default.
- W2000689318 crossrefType "journal-article" @default.
- W2000689318 hasAuthorship W2000689318A5012278399 @default.
- W2000689318 hasAuthorship W2000689318A5013090266 @default.
- W2000689318 hasConcept C150903083 @default.
- W2000689318 hasConcept C185592680 @default.
- W2000689318 hasConcept C203014093 @default.
- W2000689318 hasConcept C20418707 @default.
- W2000689318 hasConcept C207001950 @default.
- W2000689318 hasConcept C2776364478 @default.
- W2000689318 hasConcept C2779609412 @default.
- W2000689318 hasConcept C502942594 @default.
- W2000689318 hasConcept C71924100 @default.
- W2000689318 hasConcept C84425145 @default.
- W2000689318 hasConcept C86803240 @default.
- W2000689318 hasConcept C95444343 @default.
- W2000689318 hasConcept C98274493 @default.
- W2000689318 hasConceptScore W2000689318C150903083 @default.
- W2000689318 hasConceptScore W2000689318C185592680 @default.
- W2000689318 hasConceptScore W2000689318C203014093 @default.
- W2000689318 hasConceptScore W2000689318C20418707 @default.
- W2000689318 hasConceptScore W2000689318C207001950 @default.
- W2000689318 hasConceptScore W2000689318C2776364478 @default.
- W2000689318 hasConceptScore W2000689318C2779609412 @default.
- W2000689318 hasConceptScore W2000689318C502942594 @default.
- W2000689318 hasConceptScore W2000689318C71924100 @default.
- W2000689318 hasConceptScore W2000689318C84425145 @default.
- W2000689318 hasConceptScore W2000689318C86803240 @default.
- W2000689318 hasConceptScore W2000689318C95444343 @default.
- W2000689318 hasConceptScore W2000689318C98274493 @default.
- W2000689318 hasIssue "8" @default.
- W2000689318 hasLocation W20006893181 @default.
- W2000689318 hasLocation W20006893182 @default.
- W2000689318 hasOpenAccess W2000689318 @default.
- W2000689318 hasPrimaryLocation W20006893181 @default.
- W2000689318 hasRelatedWork W1976805847 @default.
- W2000689318 hasRelatedWork W2009299738 @default.
- W2000689318 hasRelatedWork W2073254795 @default.
- W2000689318 hasRelatedWork W2088444650 @default.
- W2000689318 hasRelatedWork W2118112957 @default.
- W2000689318 hasRelatedWork W2141779216 @default.
- W2000689318 hasRelatedWork W2368327561 @default.
- W2000689318 hasRelatedWork W2390723470 @default.
- W2000689318 hasRelatedWork W2393397805 @default.
- W2000689318 hasRelatedWork W2412829359 @default.
- W2000689318 hasVolume "15" @default.
- W2000689318 isParatext "false" @default.
- W2000689318 isRetracted "false" @default.
- W2000689318 magId "2000689318" @default.
- W2000689318 workType "article" @default.